

Topics of the day

- Use of molecular markers in surveillance
- FIT for surveillance
- Who deserves surveillance? Selection of patients at the highest risk after polyp removal

Rodrigo Jover (Spain)

Joaquin Cubiella (Spain)

Emma Robbins (UK)



Use of molecular markers as predictors of metachronous neoplasia

Rodrigo Jover Hospital General Universitario Dr. Balmis Alicante, Spain





WEO The voice of world endoscopy





SURVEILLANCE ADENOMAS Any adenoma > 1 cm > 5 adenomas High grade dysplasia **SERRATED POLYPS** • > 1 cm With dysplasia









Surveillance

- Size of lesions: reflects molecular and genetic impairment
- Number of lesions: reflects potential colonic factors, potential quality aspects
- Pathology factors: reflects molecular and genetic development

• Can we go beyond classical risk factors???




Why people with polyps excised are at a higher risk of developing new lesions?

- 1. Overlooked lesions: Suboptimal quality of baseline procedure
- 2. Field effect: there is "something" in the "normal" colonic mucosa



Some high risk factors select patients at the highest risk



Baile-Maxía, CGH 2023

Risk category	RR for CRC risk				
KISK Category	Compared with NAA	Compared with normal colonoscopy			
HRA	2.56 [2.21-2.96]	2.92 [2.29-3.73]			
Size ≥ 20mm	3.81 [2.19-6.63]				
Size ≥ 10mm	1.66 [1.30-2.13]	2.61 [2.06-3.32]			
HGD	2.89 [1.88-4.44]	6.62 [4.60-9.52]			
Villous component	1.75 [1.33-2.31]	3.58 [2.24-5.73]			
≥ 5 adenomas	1.36 [0.54-3.46]				
≥ 3 adenomas	1.24 [0.84-1.83]	2.03 [1.40-2.94]			

Clinical Gastroenterology and Hepatology



Why molecular markers can be better than traditional risk factors?

- Markers that summarize the real risk factor beyond size and number of lesions
- Molecular markers can reflect the reason for the risk of developing new or multiple lesions
- Perhaps these markers can help to select people at the highest risk



DOK1-MTMR7

Tumor suppressors EGFR-RAS pathway


Table IV. Logistic regression using a stepwise selection model for segmental recurrence

Stepwise selection model	of logistic regression	for segmental recurrence

Stepwise selec	tion model of logistic	regression for	segmental recu	urrence			
Case-related a	nalysis of DOK1 & M	TMR7					
	Tissue type	Odds ratio	95%CI	Coefficient	SE	p value	ROC AUC
DOK1	Non-dysplastic	1.62	1.1-1.39	0.482	0.199	0.0155 *	0.78
MTMR7	Non-dysplastic	0.57	0.95-1.98	-0.561	0.286		
Adenoma-related analysis of MTMR7							
	Tissue type	Odds ratio	95% CI	Coefficient	SE	p value	ROC AUC
MTMR7	Dysplastic	0.43	0.22 - 0.84	-0.846	0.340	0.0129 *	0.76
	1 61						

Confidence level 95%. CI: confidence interval, SE: standard error, ROC: receiver operator characteristics, AUC: area under the curve. * = p < 0.05.


Gutting, J Gastrointest Liv Dis 2021








Chromosomal instability pathway









Habermann, Modern Pathol 2011















Table 5. Predictive factors of metachronous risk lesions (multivariate analysis)

	Surveillance colonoscopy					
Basal characteristics	AAs OR (95% CI)	Proximal AA OR (95% CI)	≥3 polyps OR (95% CI)	High risk lesions (AA and/or multiplicity OR (95% CI)) Large serrated lesions OR (95% CI)	
Age 60–69	1.55 (0.76–3.14)	3.59 (1.29–9.93)	1.34 (0.71–2.54)	1.51 (0.87–2.60)	0.91 (0.27–3.21)	
Gender (female)	2 (1–4)	3.12 (1.31–7.69)	1.21 (0.60–2.45)	1.40 (0.77–2.53)	2.84 (0.73–11.05)	
Smoker/former	1.74 (0.85–3.58)	0.95 (0.38–2.33)	1.64 (0.85–3.20	1.69 (1.00–2.86)	4.82 (1.05-22.02)	
Dyslipidemia	1.03 (0.53–2.02)	0.86 (0.37–2.01)	2.47 (1.33–4.57)	1.68 (1.00–2.79)	0.71 (0.20–2.45)	
≥3 polyps	3.01 (1.44–6.27)	4.42 (1.66–11.75)	2.93 (1.48–5.81)	2.35 (1.35-4.10)	3.70 (0.81–16.83)	
>1 colonoscopy	1.21 (0.56–2.57)	1.82 (0.72–4.64)	1.74 (0.90–3.38)	1.64 (0.92–2.93)	3.64 (1.16–11.34)	
Adenoma size ≥20 mm	0.92 (0.41–2.09)	0.69 (0.23–2.02)	0.94 (0.46–1.94)	1.04 (0.56–1.93)	2.33 (0.68-8.8.03)	
NRAS	1.23 (0.25–6.07)	1.87 (0.35.9.93)	1.05 (0.18–5.96)	1.08 (0.26-4.49)	4.45 (0.43-46.51)	
MLH1	3.06 (0.57–16.21)	15.21 (3.07–76.58)	4.09 (0.88–18.95)	4.03 (0.99–16.43)		

Carot, Clin Transl Gastroenterol 2021







Serrated polyps: MLH1

Molecular characteristics	Among i	Among index SSA/Ps, n = 169				Among index right-sided SSA/Ps only, n = 137				
	Cases n (%)	Controls n (%)	Adjusted OR ^a	95%	CI	Cases n (%)	Controls n (%)	Adjusted OR ^b	95%	СІ
BRAF mutation										
Wildtype	6 (35)	42 (28)	1.00	Ref		3 (25)	29 (24)	1.00	Ref	
Mutant	11 (65)	110 (72)	0.74	0.24	2.27	9 (75)	90 (76)	0.78	0.18	3.34
CIMP										
No	8 (47)	79 (48)	1.00	Ref		6 (50)	50 (40)	1.00	Ref	
Low	6 (35)	66 (40)	0.98	0.32	3.03	3 (25)	60 (48)	0.53	0.12	2.43
High	3 (18)	18 (11)	1.67	0.38	7.33	3 (25)	15 (12)	1.30	0.33	5.19
MLH1 methylation										
PMR ≤ 10	15 (88)	156 (97)	1.00	Ref		10 (83)	121 (98)	1.00	Ref	
PMR > 10	2 (12)	5 (3)	4.66	1.06	20.51	2 (17)	3 (2)	6.00	2.12	16.9


Hua, Cancer Causes Control 2020





Murcia, Cancers 2021

CIMP



Time to first MACL (months)



KRAS restrospective study

and sex.

OUTCOME

Factors included in the analysis

ADVANCED ADENOMAS

Molecular Classification

-Wild-type Group

-BRAFGroup

-KRASGroup

ADVANCED SERRATED LESIONS

No Previous CRC

Previous CRC

Adenomas Size <10 mm or no adenomas

Adenomas Size \geq 10 mm

ANY ADVANCED POLYP

Molecular Classification

-Wild-type Group

-BRAFGroup

-KRASGroup

Juárez, PLOSone 2017




Table 4. Multivariate analysis of clinical and molecular characteristics of patients, adjusted for age

OR	95% CI		P-value
	Min.	Max.	
1			
0.99	0.31	3.12	1.0
2.23	1.02	4.85	0.044
1			
2.17	0.85	5.53	0.1
1			
0.40	0.15	1.05	0.1
1			
1.08	0.43	2.71	0.9
2.27	1.15	4.46	0.018








any advanced polyp or (B) advanced adenomas over time.

Juárez, PLOSone 2017

Fig 2. Risk of developing advanced polyps based on KRAS mutational status at baseline colonoscopy. Kaplan-Meier curves show the proportions of patients with WT or KRAS-mutated lesions that developed either (A)



BRAF retrospective



advanced polyp or (B) advanced adenoma over time.

Juárez, PLOSone 2017





Fig 1. Risk of developing advanced polyps based on BRAF mutational status at baseline colonoscopy. Kaplan-Meier curves show the proportions of patients with WT or BRAF-mutated lesions that developed either (A) any





HOSPITAL GENERAL UNIVERSITARIO DE ALICANT







KRAS prospective EPoS II-3 years 518 patients with high-risk adenomas

	KRAS WILD-TYPE 1099 (92.4%)	KRAS MUTATED 90 (7.6%)
TYPE OF ADENOMA Tubular	782 (95.2%)	39 (4.8%)
Tubulo-villous Villous	176 (79.6%) 6 (75.0%)	45 (20.4%) 2 (25.0%)
SIZE <10 10-19 >20	688 (96.8%) 345 (88.2%) 66 (75.9%)	23 (3.2%) 46 (11.8%) 21 (24.1%)
DYSPLASIA High Low	31 (79.5%) 1068 (92.9%)	8 (20.5%) 82 (7.1%)
ADVANCED ADENOMA Yes No	460 (86.0%) 639 (97.7%)	75 (14.0%) 15 (2.3%)

Martínez-Roca, UEGW 2022



KRAS prospective

Characteristics at

Age, median (IQ

Sex, n (%)

Male

Female

HISTOLOGY, n (

Serrated lesio

Adenomas

ADVANCED SERRATED PO

No

Yes

ADVANCED ADENOM

No

Yes

Martínez-Roca, UEGW 2022

	Univari	Multivariate Ana	
baseline		OR (95%CI)	OR (95%CI)
QR)	67 (61-70)	1.06 (1.02-1.10)	1.06 (1.03-1.11)
	84 (25.4)	1	
	35 (18.7)	1.47 (0.95-2.30)	
(%)			
ons	25 (29.1)	1	
S	94 (21.8)	1.47 (0.87-2.47)	
POLYPS, n (%)		1	
	111 (22.2)	1	1
	8 (42.1)	2.54 (1.00-6.47)	2.67(0.97-7.28)
MA, n (%)			
	1 (33.3)	1	
	118 (22.9)	0.59 (0.53-6.61)	

aly	sis
I)	_

KRAS prospective

Martínez-Roca, UEGW 2022

ADENOMA NUN

- <
 - 3
 - 2
- PROXIMAL POL
 - N
 - Ye
- **VILLOUS HISTO**
 - _____
 - N
 - Ye
 - ≥20MM POLY
 - N
 - Ye
 - HGD, n
 - Ν
 - Ye
 - **KRAS MUTAT**
 - Ν
 - Y
 - Ye

MBER, n (%)				
<3	46 (16.5)	1	1	
3-4	41 (23.8)	4.54 (2.56-8.33)	4.32 (2.36-7.88)	
≥5	32 (47.1)	2.84 (1.56-5.26)	2.88 (1.54-5.34)	
DLYPS, n (%)				
No	39 (16.3)	1	1	
/es	80 (28.9)	2.10 (1.36-3.23)	1.06 (0.62-1.83)	
OLOGY, n (%)				
No	73 (22)	1		
/es	46 (24.7)	1.16 (0.76-1.77)		
YPS, n (%)				
No	100 (22.5)	1		
/es	19 (25.7)	1.18 (0.67-2.10)		
า (%)				
No	112 (23)	1		
es	7 (21.9)	0.93 (0.40-2.21)		
TION, n (%)				
No	86 (19.5)	1	1	
es	33 (42.3)	3.02 (1.81-5.02)	3.30 (1.92-5.65)	



Molecular markers for surveillance

- Potential use to go beyond traditional risk markers • Potentially able to select patients at the highest risk
- Prospective studies
- More research is needed
- Markers of field effect







World Endoscopy Organization

